News
Stay up-to-date on ReadyCell’s latest news, projects and developments.
A new study that uses CacoReady reveals a potent inhibitor for prostate cancer
Evaluating in vitro permeability with CacoReady plates was central to the study design. By quantifying the permeability of the synthesized compounds within Caco-2 cells, researchers could identify and select which compounds were best in terms of cellular adsorption.
Gel-like matrix, an innovative solution for in vitro cell preservation
This innovative biotechnology is available to transport living cells at room temperature.
Seminar: Emerging Trends and Challenges in Customer Journey
In a new edition of the ReadyCell presentation’s cycle, Carla shared her expertise about the customer experience business model, the different acquisition methods, and the potential of online platforms.
Strategies for successful Drug Discovery and Development at the BTS Discovery Toxicology 2023
Lourdes Gombau, head of the R&D Department, and Maria Riba, Business Development Manager, presented in the UK the last scientific article of the company, shedding light on the topic of compound intestinal toxicity.
Presenting the last advances in transporters in Germany
On May 15-17, the 22nd Barrier- and Transporter- days took place in Germany. At the event, Jonatan Cucala, R&D researcher at ReadyCell, presented a poster entitled “PreadyTake, an in vitro ready-to-use cell-based model to evaluate potential drug-transporter interactions.”
ReadyCell promotes continuous learning through in-house seminars
Last Thursday, R&D Director Lourdes Gombau presented “Women and Science”, a seminar that aimed to raise awareness of the role of women in the scientific field throughout history and at present.
MPS-LOC: Microphysiological systems based on liver on chip for drug discovery and testing
ReadyCell is partaking in a new collaborative project together with Leitat Technological Center and Vall d’Hebron Institute of Research (VHIR). The project aims to develop microphysiological systems based on liver-on-chip for drug discovery and testing.
Why evaluate MDR1 receptor affinity in CNS pharmacokinetic assays?
MDCKII cells based in vitro system is a recommended model to evaluate blood-brain barrier permeability during CNS action novel compounds.
Cytotoxicity Assay Protocol
Through this protocol we offer our CacoReady plates for assessing drug-associated gastrointestinal side effects.
StretchBio holds its 18-month meeting
Our representatives participated in the 18-month meeting of the StretchBio project, held in Freiburg. The meeting was focused on the design and operation of the functional prototype of the sensor.
Happy International Women’s Day!
With this infographic, we proudly show the key facts we have achieved in recent times in promoting gender equality and women’s rights in the company.
Toxicological evaluation of chemicals and the implications of human P-gp and BCRP transporters
Publications have confirmed the importance of developing safe chemical agents using membrane transporter analysis as a criterion. This is reflected in the field of pesticides, one of the areas in which this analysis has been most widely applied.
3DLIVER: Innovative Human-Derived 3D Liver Models for Drug Toxicity Testing and Discovery
The main objective of this project is to develop novel 3D in vitro tools derived from the human liver, relevant to the discovery and preclinical phases of drug development.
Caco-2 based in vitro models for the screening of anti-inflammatory drugs
Inflammatory reactions of the intestinal tract are the result of a combination of hereditary, genetic and/or environmental factors that have been clustered in the inflammatory bowel disease (IBD). ReadyCell has available CacoReady and CacoGoblet to assay compounds inflammatory properties.
